

2<sup>nd</sup> edition

# Unmet challenges in high risk hematological malignancies: from benchside to clinical practice

Turin, September 13-14, 2021

Starhotels Majestic

*Scientific board:*

**Marco Ladetto** (Alessandria)

**Umberto Vitolo** (Candiolo-TO)



## AUSPICES

UNIVERSITÀ DEL PIEMONTE ORIENTALE

ISTITUTO DI CANDIOLO - FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA - IRCCS

AZIENDA OSPEDALIERA DI ALESSANDRIA SANTI ANTONIO E BIAGIO E CESARE ARRIGO

UNIVERSITÀ DI TORINO

AZIENDA OSPEDALIERO-UNIVERSITARIA

Città della Salute e della Scienza di Torino - Presidio Ospedaliero Le Molinette

FIL - FONDAZIONE ITALIANA LINFOMI

GITMO - Gruppo Italiano per il Trapianto di Midollo Osseo,  
cellule staminali emopoietiche e terapia cellulare

SIE - SOCIETÀ ITALIANA DI EMATOLOGIA

SIES - SOCIETÀ ITALIANA DI EMATOLOGIA SPERIMENTALE

RETE ONCOLOGICA DEL PIEMONTE E DELLA VALLE D'AOSTA

## FACULTY

<b>Emanuele</b>	<b>Angelucci</b>	Genoa, Italy	<b>Alessandra</b>	<b>Larocca</b>	Turin, Italy
<b>Stephen M.</b>	<b>Ansell</b>	Rochester, USA	<b>Maurizio</b>	<b>Martelli</b>	Rome, Italy
<b>Hervé</b>	<b>Avet Loiseau</b>	Toulouse, France	<b>Massimo</b>	<b>Massaia</b>	Cuneo, Italy
<b>Monica</b>	<b>Balzarotti</b>	Rozzano (MI), Italy	<b>Francesco</b>	<b>Merli</b>	Reggio Emilia, Italy
<b>Renato</b>	<b>Bassan</b>	Mestre (VE), Italy	<b>Grzegorz S.</b>	<b>Nowakowski</b>	Rochester, USA
<b>Mario</b>	<b>Boccardo</b>	Turin, Italy	<b>Owen A.</b>	<b>O'Connor</b>	Charlottesville, USA
<b>Alan K.</b>	<b>Burnett</b>	Glasgow, UK	<b>Fabrizio</b>	<b>Pane</b>	Naples, Italy
<b>Angelo Michele</b>	<b>Carella</b>	Genoa, Italy	<b>Stefano A.</b>	<b>Pileri</b>	Milan, Italy
<b>Annalisa</b>	<b>Chiappella</b>	Milan, Italy	<b>Antonio</b>	<b>Pinto</b>	Naples, Italy
<b>Daniela</b>	<b>Cilloni</b>	Turin, Italy	<b>Christiane</b>	<b>Pott</b>	Kiel, Germany
<b>Antonio</b>	<b>Cuneo</b>	Ferrara, Italy	<b>Patrizia</b>	<b>Pregno</b>	Turin, Italy
<b>Barbara</b>	<b>Eichhorst</b>	Cologne, Germany	<b>Alessandro</b>	<b>Rambaldi</b>	Bergamo, Italy
<b>Brunangelo</b>	<b>Falini</b>	Perugia, Italy	<b>Luigi</b>	<b>Rigacci</b>	Rome, Italy
<b>Simone</b>	<b>Ferrero</b>	Turin, Italy	<b>Giuseppe</b>	<b>Saglio</b>	Turin, Italy
<b>Robin</b>	<b>Foà</b>	Rome, Italy	<b>Gilles</b>	<b>Salles</b>	New York, USA
<b>Nathan H.</b>	<b>Fowler</b>	Houston, USA	<b>Valeria</b>	<b>Santini</b>	Florence, Italy
<b>Gianluca</b>	<b>Gaidano</b>	Novara, Italy	<b>Stephen J.</b>	<b>Schuster</b>	Philadelphia, USA
<b>Paolo</b>	<b>Ghia</b>	Milan, Italy	<b>Michele</b>	<b>Spina</b>	Aviano (PN), Italy
<b>Paola</b>	<b>Guglielmelli</b>	Florence, Italy	<b>Enrico</b>	<b>Tiacci</b>	Perugia, Italy
<b>Olivier</b>	<b>Hermine</b>	Paris, France	<b>Jan</b>	<b>Trka</b>	Prague, Czech Republic
<b>Peter</b>	<b>Hillmen</b>	Leeds, UK	<b>Adriano</b>	<b>Venditti</b>	Rome, Italy
<b>Martin</b>	<b>Hutchings</b>	Copenhagen, Denmark	<b>Carlo</b>	<b>Visco</b>	Verona, Italy
<b>Nicolaus</b>	<b>Kröger</b>	Hamburg, Germany	<b>Umberto</b>	<b>Vitolo</b>	Candiolo (TO), Italy
<b>Marco</b>	<b>Ladetto</b>	Alessandria, Italy	<b>Elena</b>	<b>Zamagni</b>	Bologna, Italy
			<b>Emanuele</b>	<b>Zucca</b>	Bellinzona, Switzerland

09.00 **Welcome and introduction**

*M. Ladetto, U. Vitolo and Scientific Authorities*

09.30-11.00 **Hodgkin Lymphoma and T-cell Lymphoma**

*Chairmen: A. Pinto, M. Spina*

09.30 Genetics and biology of classical Hodgkin Lymphoma: clinical implications

*E. Tiacci*

09.50 How I treat high risk Hodgkin Lymphoma

*S.M. Ansell*

10.10 Histopathology and molecular biology of T-cell Lymphoma

*S.A. Pileri*

10.30 How I treat high risk T-cell Lymphomas

*O.A. O'Connor*

10.50 Panel Discussion

11.00-11.30 **LECTURE I**

*Chairman: M. Ladetto*

**Optimizing outcomes for CD19-directed CAR-T cell therapy in refractory B-cell lymphomas**

*S.J. Schuster*

11.30-12.45 **Mantle Cell Lymphoma**

*Chairmen: M. Ladetto, M. Martelli*

11.30 Biological identification of high risk Mantle Cell Lymphoma

*C. Pott*

11.50 How I treat high risk Mantle Cell Lymphoma in first line

*O. Hermine*

12.10 How I treat relapsed/refractory Mantle Cell Lymphoma

*C. Visco*

12.30 Panel Discussion

12.45-14.00 *Lunch*

**14.00-14.30 LECTURE II**

*Chairman: U. Vitolo*

**Impact of Lugano conferences in the lymphoma research**

*E. Zucca*

**14.30-16.00 Diffuse large B-Cell Lymphoma**

*Chairmen: M. Balzarotti, U. Vitolo*

14.30 Biological identification of high risk DLBCL

*G. Gaidano*

14.50 How I treat high risk DLBCL in first line

*A. Chiappella*

15.10 How I treat DLBCL in relapse

*G.S. Nowakowski*

15.30 Novel antibodies in aggressive lymphomas

*M. Hutchings*

15.50 Panel Discussion

**16.00-17.10 Follicular Lymphoma**

*Chairmen: F. Merli, L. Rigacci*

16.00 Biological of high risk Follicular Lymphoma

*S. Ferrero*

16.20 How I treat high risk Follicular Lymphoma in first line

*G. Salles*

16.40 How I treat relapsed/refractory Follicular Lymphoma

*N.H. Fowler*

17.00 Panel Discussion

**17.10-18.20 Chronic Lymphocytic Leukemia**

*Chairmen: A. Cuneo, P. Ghia*

17.10 Biology of high risk Chronic Lymphocytic Leukemia

*M. Massaia*

17.30 Defining high risk Chronic Lymphocytic Leukemia in 2021 from the clinician's perspective

*B. Eichhorst*

17.50 How I treat relapsed/refractory Chronic Lymphocytic Leukemia

*P. Hillmen*

5 18.10 Panel Discussion

**9.15-10.25 Multiple Myeloma**

*Chairmen: M. Boccadoro, M. Massaia*

09.15 Biology of high risk Multiple Myeloma  
*H. Avet-Loiseau*

09.35 How I treat young high risk Multiple Myeloma  
*E. Zamagni*

09.55 How I treat elderly high risk Multiple Myeloma  
*A. Larocca*

10.15 Panel Discussion

**10.30-11.00 LECTURE III**

*Chairman: G. Saglio*

**Beyond 3+7 in Acute Myelogenous Leukemia**  
*A.K. Burnett*

**11.00-12.10 Myeloproliferative Disorders**

*Chairmen: A.M. Carella, G. Saglio*

11.00 Biology of high risk myeloproliferative disorders  
*P. Guglielmelli*

11.20 How I treat high risk Chronic Myeloid Leukemia  
*P. Pregno*

11.40 How I treat high risk myeloproliferative neoplasms  
*D. Cilloni*

12.00 Panel Discussion

12.10-13.10 *Lunch*



**13.10-14.20 Acute Lymphoblastic Leukemia and Transplantation**

*Chairmen: R. Foà, A. Rambaldi*

- 13.10 Biology of High Risk Acute Lymphoblastic Leukemia  
*J. Trka*
- 13.30 How I treat high risk Acute Lymphoblastic Leukemia in first line  
*R. Bassan*
- 13.50 Allogeneic transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndromes  
*N. Kröger*
- 14.10 Panel Discussion

**14.20-15.30 Acute Myeloblastic Leukemia and Myelodysplastic Syndrome**

*Chairmen: E. Angelucci, F. Pane*

- 14.20 Genomic identification of high risk Acute Myeloid Leukemia  
*B. Falini*
- 14.40 How I treat high risk Myelodysplastic Syndromes  
*V. Santini*
- 15.00 How I treat elderly Acute Myeloid Leukemia patients  
*A. Venditti*
- 15.20 Panel Discussion
- 15.30-15.45 **Closing remarks**  
*M. Ladetto, U. Vitolo*

With an unrestricted educational grant of:

abbvie

astellas

Karyopharm  
Therapeutics

AstraZeneca

BeiGene

Celgene

gsk

Roche

AMGEN

GILEAD

Incyte | SOLVE  
ON.

janssen Oncology  
PHARMACEUTICAL COMPANY OF Johnson & Johnson

NOVARTIS

Pfizer

SANDOZ A Novartis  
Division

## GENERAL INFORMATION

### MEETING VENUE

#### Starhotels Majestic

Corso Vittorio Emanuele II, 54  
10123 Torino, Italy  
Tel. +39 011 539153

### ITALIAN CME CREDITS

An Italian CME application has been submitted as follows:

- Provider Studio ER Congressi SRL: ID 828- 282393.
- No. 9,1 CME credits for Physicians (Haematology, Oncology, Internal Medicine) and Biologists.
- Educational objective: "linee guida-protocolli-procedure".

### OFFICIAL LANGUAGE

English

### BADGE AND CERTIFICATE OF ATTENDANCE

All registered participants and speakers will be given a badge which must be worn in order to be admitted to the scientific sessions.  
A certificate will be given to all participants at the end of the meeting.



The organization is proud to compensate its greenhouse gas emissions investing in the carbon offset project: "Mytrah Wind Power".

### SCIENTIFIC BOARD

#### Marco Ladetto MD

Associate Professor in Haematology  
University of Eastern Piedmont Amedeo Avogadro  
S.S. Antonio and Biagio and Cesaro Arrigo  
Via Venezia, 16 – 15121 Alessandria, Italy

#### Umberto Vitolo MD

Hematology Consultant  
Candiolo Cancer Institute - FPO-IRCCS  
Strada Provinciale, 142 - 10060 Candiolo (TO), Italy

### SCIENTIFIC COMMITTEE

Prof. Mario Boccadoro (Turin)

Prof. Gianluca Gaidano (Novara)

Prof. Massimo Massaia (Cuneo)

Prof. Giuseppe Saglio (Orbassano - TO)

### ORGANIZING SECRETARIAT

#### Studio E.R. Congressi

Via De' Poeti, 1/7 - 40124 Bologna, Italy  
Phone +39 051 4210559 - Fax +39 051 4210174  
E-mail: [ercongressi@ercongressi.it](mailto:ercongressi@ercongressi.it)  
[www.ercongressi.it](http://www.ercongressi.it)